| News & Announcements | Nutritional Counseling/Medical Nutrition Therapy for Independence Members | | | | | | 9/11/2023 | | | |
| News & Announcements | Coverage of the COVID-19 Vaccination for Independence Commercial Members (Updated on September 22, 2023) | | | | | | 9/22/2023 | | | |
| News & Announcements | 10/01/2023 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products | | | | | | 9/28/2023 | | | |
| News & Announcements | Coverage of Respiratory Syncytial Virus Immunizations for Independence Commercial Members (Updated September 28, 2023) | | | | | | 9/28/2023 | | | |
| Notifications | Abatacept (Orencia®) for Injection for Intravenous Use | 08.00.62o | 9/12/2023 11:00 AM | 12/11/2023 | | | 9/12/2023 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Notifications | Nebulizers and Inhalation Solutions | 05.00.15t | 9/29/2023 11:00 AM | 1/1/2024 | | | 9/29/2023 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| New Policies | Beremagene Geperpavec (Vyjuvek™) | 08.02.10 | | 9/11/2023 | | | 9/11/2023 | This is a New Policy. | | |
| Updated Policies | Durvalumab (Imfinzi®) and tremelimumab-act (Imjudo®) | 08.01.65c | | 9/4/2023 | | | 9/1/2023 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | High-Technology Radiology Services (Independence) | 09.00.46ao | | 9/10/2023 | | | 9/11/2023 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Musculoskeletal Services (Independence) | 00.01.66i | | 9/10/2023 | 9/10/2023 | | 9/11/2023 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Sleep Disorder Testing and Positive Airway Pressure Therapy Services and Supplies | 07.03.05z | | 9/10/2023 | 9/11/2023 | | 9/11/2023 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Pressure-Reducing Support Surfaces | 05.00.60j | | 9/11/2023 | | | 9/11/2023 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and combination VEGF/Angiopoietin-2 (Ang-2) inhibitors | 08.00.74s | 6/20/2023 9:00 AM | 9/18/2023 | | | 9/18/2023 | Medical Necessity Criteria | | |
| Updated Policies | Catheter Ablation of Cardiac Arrhythmias | 11.02.06p | | 9/25/2023 | | | 9/25/2023 | Medical Necessity Criteria | | |
| Updated Policies | Knee Orthoses | 05.00.47q | | 9/25/2023 | | | 9/25/2023 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | |
| Updated Policies | Reduction Mammoplasty | 11.08.02k | | 9/25/2023 | | | 9/25/2023 | Medical Necessity Criteria | | |
| Updated Policies | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | 11.16.01k | | 9/25/2023 | | | 9/25/2023 | Coverage and/or Reimbursement Position;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Obstetrical Ultrasounds for Members Enrolled in a Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Product | 00.03.10F | | 9/25/2023 | | | 9/25/2023 | Coverage and/or Reimbursement Position | | |
| Updated Policies | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative Services | 00.01.25bk | | 9/25/2023 | | | 9/25/2023 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Palivizumab (Synagis) | 08.00.22q | | 9/25/2023 | | | 9/25/2023 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Outpatient Short-Term Rehabilitation Services Included in Capitation | 00.03.03i | | 9/25/2023 | | | 9/25/2023 | Coverage and/or Reimbursement Position | | |
| Reissue Policies | Bone-Anchored (Osseointegrated) Hearing Aids and Implantable Middle Ear Hearing Aids | 11.01.06g | | 1/1/2023 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Cranial Electrotherapy Stimulation | 05.00.80c | | 1/1/2023 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®) | 08.01.23i | | 10/4/2021 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Modifiers for Split or Shared Surgical Services (Modifiers 54, 55, and 56) | 03.00.31g | | 10/25/2021 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | National Correct Coding Initiative (NCCI) Code Pair Edits | 00.01.56b | | 1/3/2022 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Modifier 52: Reduced Services | 03.00.32b | | 12/6/2021 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Modifier 53: Discontinued Procedure | 03.00.33b | | 12/6/2021 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Transcatheter Closure of Cardiac Septal Defects | 11.02.11h | | 10/1/2022 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | First-Trimester Prenatal Screening for Fetal Aneuploidy Using Fetal Ultrasound Markers | 09.00.36m | | 11/21/2022 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Home Health Care Services | 02.01.01f | | 8/29/2022 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation | 11.02.26c | | 7/18/2022 | 9/6/2023 | | 9/6/2023 | | | |
| Reissue Policies | Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®) | 08.01.36e | | 7/1/2020 | 9/6/2023 | | 9/11/2023 | | | |
| Reissue Policies | Etranacogene dezaparvovec-drlb (Hemgenix ®) | 08.02.03 | | 5/22/2023 | 9/6/2023 | | 9/11/2023 | | | |
| Reissue Policies | Bioimpedence for the Detection of Lymphedema | 07.06.03b | | 12/29/2014 | 9/20/2023 | | 9/20/2023 | | | |
| Reissue Policies | Radioimmunotherapy with Ibritumomab Tiuxetan (Zevalin®) (Independence Administrators) | 08.00.08j | | 3/4/2019 | 9/20/2023 | | 9/20/2023 | | | |
| Reissue Policies | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | 05.00.74h | | 12/5/2022 | 9/20/2023 | | 9/20/2023 | | | |
| Reissue Policies | Endovascular Stent-Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal Lesions | 11.02.17h | | 10/1/2022 | 9/20/2023 | | 9/20/2023 | | | |
| Coding Update | Genetic Testing (Independence Administrators) | 06.02.35ak | | 7/1/2023 | | | 9/18/2023 | | | |
| Coding Update | Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®) | 08.00.50ab | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Acupuncture | 12.00.01h | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Biofeedback Therapy | 07.00.01k | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | 05.00.74i | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM) Devices | 07.02.09i | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Electroconvulsive Therapy (ECT) | 14.00.01a | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level Devices | 05.00.30p | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Anesthesia Services for Epidural, Paravertebral Facet and Sacroiliac Joint Injections for Spinal Joint Management | 01.00.12b | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Home-Based Sleep Studies | 07.03.01c | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Cranial Remolding Orthoses (Helmets) | 05.00.25j | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | 07.02.21m | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Automatic External Cardioverter Defibrillators (Wearable and Nonwearable) | 05.00.29o | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Esophagogastroduodenoscopy (EGD) and Endoscopic Retrograde Cholangiopancreatography (ERCP) | 07.02.22f | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for Treating Life-threatening Ventricular Tachyarrhythmia | 05.00.77d | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Treatment of Obstructive Sleep Apnea (OSA) and Primary Snoring | 11.00.06q | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Catheter Ablation of Cardiac Arrhythmias | 11.02.06q | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders | 07.05.02r | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Cardiac Rehabilitation (CR) and Intensive Cardiac Rehabilitation (ICR) Programs | 10.01.01p | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Electromyography (EMG) Studies: Needle EMG, Surface EMG (SEMG) | 07.03.09u | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Nerve Conduction Studies (NCS) and Related Electrodiagnostic Studies | 07.03.18t | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Deep Brain Stimulation (DBS) | 11.15.20s | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Trilaciclib (Cosela™) | 08.01.77d | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Electromyography (EMG) (Needle and Non-Needle) of the Anal or Urethral Sphincter | 07.03.21n | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Mentoplasty or Genioplasty | 11.14.01h | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Neuropsychological Testing for Neurologically Based Conditions | 07.03.08n | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Vagus Nerve Stimulation (VNS) | 11.15.16t | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | crizanlizumab-tmca (Adakveo®) | 08.00.04a | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG) | 08.00.13ag | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Self-Administered Drugs | 08.00.78ao | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Nutritional Formulas, Enteral Nutrition, Medical Foods, Low-Protein Modified Food Products, and Donated Breast Milk | 08.00.18p | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | 08.01.08n | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Intravenous Chelation Therapy | 07.00.02j | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | 11.08.20ah | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Bortezomib (Bortezomib for Injection, Velcade®) | 08.00.73p | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Repository Corticotropin Injection (Acthar® Gel, Purified Cortrophin[TM] Gel) | 08.01.12d | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Retifanlimab-dlwr (Zynyz TM) | 08.02.05a | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Denosumab (Prolia®, Xgeva®), Romosozumab-aqqg (Evenity®) | 08.00.94q | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Botulinum Toxin Agents | 08.00.26ab | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Eptinezumab-jjmr (VYEPTI™) | 08.00.45d | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Abatacept (Orencia®) for Injection for Intravenous Use | 08.00.62o | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Prescription Lenses and Visual Devices | 07.13.13f | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Treatment of Medical and Surgical Complications | 11.00.02h | | 10/1/2023 | | | 9/29/2023 | | | |
| Coding Update | Mohs Micrographic Surgery | 11.08.23k | | 10/1/2023 | | | 9/29/2023 | | | |
